Hiroaki Takaya - Concepedia

Author

Hiroaki Takaya

Nara Medical University ORCID

Also Known As

H Takaya, H. Takaya, HIROAKI TAKAYA, Hiroaki Takaya

133

Publications

Citations

H-Index

Concepts

All Affiliations

Nara Medical University Nara Medical University Hospital

About

Hiroaki Takaya is an author at Nara Medical University specializing in liver physiology, medicine, and hepatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	17	400
2	Health Sciences	8	8	174
3	Allergy	1	1	14
4	Biochemistry	1	1	84
5	Cell Biology	1	1	27

Hiroaki Takaya

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity Kosuke Kaji, Hiroaki Takaya, Soichiro Saikawa, World Journal of Gastroenterology	2017	99
Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nrf2-mediated antioxidant response and acetaldehyde metabolization with inhibition of the LPS/TLR4 signaling pathway Koji Ishida, Kosuke Kaji, Shinya Sato, The Journal of Nutritional Biochemistry InflammationAcetaldehyde MetabolizationHepatologyBiochemistryMedicine	2020	84
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis Masanori Furukawa, Kei Moriya, Jiro Nakayama, Hepatology Research	2020	76
ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child‐Turcotte‐Pugh score and the Model for End‐Stage Liver Disease score Hiroaki Takaya, Masahito Uemura, Yoshihiro Fujimura, Hepatology Research	2012	49
von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C Hiroaki Takaya, Hideto Kawaratani, Yuki Tsuji, United European Gastroenterology Journal	2018	48
Thyroid‐stimulating hormone is an independent risk factor of non‐alcoholic fatty liver disease Kazuki Tahara, Takemi Akahane, Tadashi Namisaki, JGH Open	2019	46
Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients Kosuke Kaji, Soichiro Saikawa, Hiroaki Takaya, Antibiotics	2020	41
VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma Hiroaki Takaya, Tadashi Namisaki, Mitsuteru Kitade, BMC Gastroenterology	2019	37
Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure Hiroaki Takaya, Hitoshi Yoshiji, Hideto Kawaratani, Biomedical Reports	2017	35
Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis Yukihisa Fujinaga, Hideto Kawaratani, Daisuke Kaya, International Journal of Molecular Sciences	2020	35

Page 1